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Summary. Galectins are vertebrate lectins interacting 
with B-galactosides and derivates thereof such as blood 
group A, B and H determinants. The expression of 
galectin-l and -3 and galectin-specific binding sites by 
human Sertoli cells was analyzed in normal human testis 
and Sertoli cell only-syndrome (SCOS). Staining 
intensity was scored semiquantitatively on a 4-grade 
scale. Sertoli cells in normal testes displayed a moderate 
cytoplasmic and weak nuclear staining for galectin-l- 
specific binding sites. Galectin-3-specific binding sites 
were expressed in Sertoli cells less intensely than 
accessible ligands for galectin-l (mean score 2.25 for 
galectin-l and 1.50 for galectin-3). Germ cells were only 
weakly reactive. Tubular walls were negative for both 
classes of galectin-specific binding sites. In SCOS, 
galectin-l binding was moderate to strong and more 
pronounced than galectin-3 binding by Sertoli cells 
(mean scores 4.00 and 2.25). Tubular walls were 
negative for galectin-staining. The ratio for galectin-1-1 
galectin-3-specific binding (staining score ratio) was 
1.50 form normal testis and 1.78 for SCOS disclosing a 
relative increase of galectin-3 binding sites in the latter. 
Staining with galectin-l- and -3-specific antisera showed 
a strong cytoplasmic galectin-l immunoreactivity in 
Sertoli cells of normal and SCOS testis (score 4.00 for 
both). Anti-galectin-3 did not stain Sertoli cells or germ 
cells in normal testis. Only Leydig cells were labeled 
(score 3.00). In SCOS a weak to moderate nuclear 
staining of Sertoli cells was noted (score 2.00). 
Galectin-3 expression and galectin-l-specific 
binding sites were found to be increased in Sertoli cells 
of SCOS. This modulation of reactivity can have 
implications for Sertoli cell interactions with galectin- 
reactive extracellular matrix components like laminin 
and for anti-apoptotic effects. 
Key words: Sertoli cell only-syndrome, Galectin, 
Human testis, Leydig cells 
Offprint requests to: Prof. U. Wollina, Department of Dermatology, 
University of Jena, Erfurter Str. 35. D-07740 Jena. Germany. e-mail: 
uwol@derma.uni-jena.de 
Introduction 
Galectins constitute a protein family with conserved 
sequence elements in the carbohydrate-binding site. 
They are characterized as vertebrate lectins binding to 
gal-B1,4(3)-GlcNAc cores and extended structures 
establishing A, B or H-blood group epitopes in a 
species- and galectin type-dependent manner, as 
documented by determination of the ligand features in 
specific assays as well as by NMR spectroscopy and X- 
ray analysis of galectinlligand-complexes (Hirabayashi, 
1997; Hughes, 1997; Gabius, 1997a, 1998; von der Lieth 
et al., 1998). By interaction with B-galactosides on 
glycans of glycolipids they are involved in cell-cell 
interactions, cell adhesion to extracellular matrix 
components and proliferation control (Gabius, 1997a; 
Zanetta, 1997; Kaltner and Stierstorfer, 1998). 
Moreover, additional capacity to be engaged in protein 
contacts can play a role for the activity of galectin-l and 
-3 in pre-mRNA processing (Patterson et al., 1997). 
Glycohistochemical tissue analysis is commonly 
based on the monitoring with plantlinvertebrate lectins, 
providing a detailed mapping of the expression of 
carbohydrate epitopes. Lectin application has only 
recently been extended to the use of endogenous lectins 
as tools (Bardosi et al., 1990; Gabius et al., 1993; Brinck 
et al., 1995; Gabius, 1997b). While lectin histochemical 
studies on glycoconjugate expression in vertebrate testes 
including human are available (Arya and Vanha-Perttula, 
1984; Malmi et al., 1987; Wollina et al., 1989a; Lemaire 
and Heinlein, 1992; Wine and Chapin, 1997), expression 
of galectins and galectin-specific binding sites have not 
been studied so far. Galectin-l and -3 are the best 
characterized members of the galectin family. Among ist 
activities galectin-l appears to be involved in the 
organization of extracellular matrix, in cell contact 
formation and in biosignaling. In human cytotropho- 
blasts, galectin-l is colocalized with laminin (Vicovac et 
al., 1998). When interacting with the ganglioside GM1 
on human neuroblastoma cells, their proliferative 
activity is reduced and differentiation is triggered 
(Kopitz et al., 1998). Another intriguing role in growth 
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control is played by galectin-3. It inhibits apoptosis 
through a cysteine protease pathway, without altering 
Bcl-2, Bcl-X(L), or Bax expression (Yang et al., 1996; 
Akahani et al., 1997). Interestingly, the pattern of 
expression of galectins is not necessarily identical, as 
initially demontrated in human and murine tumors and in 
normal tissue such as the reproductive tract of pregnant 
mice or trophoblasts (Gabius et al., 1986a,b; Phillips et 
al., 1996; Gabius, 1997b;  Maquoi e t  al., 1997; 
Ohannesian and Lotam, 1997). The present study 
compares the expression and distribution of two 
galectins, namely galectin-l and -3, and their specific 
binding sites in normal human testes and in Sertoli cell 
only-syndrome (SCOS). 
Materials and methods 
Tissue samples from normal human testes (n=4) and 
SCOS (n=4) have been obtained from the files of the 
Andrology Unit at the Department of Dermatology, 
University of Jena. The patient's mean age was 29.8 
years for normal testes (range 27 to 32 years) and 26.7 
years (range 21  to 31  years) for SCOS. The tissue 
specimens were fixed in Bouin's solution and embedded 
in paraffin after common dehydration. 
Galectin-l and -3 have been prepared as described 
recently (Gabius et al., 1991; Siebert et al., 1997). They 
were biotinylated with biotinyl-N-hydroxysuccimide 
ester in presence of lactose to protect the active site 
(Bardosi et al., 1990). Galectin-l- and -3-specific 
polyclonal antisera were raised in rabbits and controlled 
rigorously for the lack of cross-reactivity (Kopitz et al., 
1998). Lectin- and immunohistochemical staining were 
performed on 4 pm-thick sections, dewaxed, rehydrated 
and treated subsequently with 1% methanolic H202 for 
30 min to block endogenous peroxidase activity. The 
sections were rinsed in phosphate-buffered saline (PBS 
buffer; pH 7.4) and incubated with 0.1% bovine serum 
albumin in PBS buffer for 30 min to block nonspecific 
protein-binding sites. Biotinylated galectins-l and -3 
were used at a final concentration of 1 pg/ml and applied 
overnight at 4 'C. Thorough washes, application of 
commercial avidin-peroxidase kit reagents ( ~ a x i ~ a ~ s @ ,  
Quartett, BerlinIGermany), repetitive rinses and 
development of the chromogenic product from 9-amino- 
ethylcarbazole as substrate concluded the processing. 
Fig. 1. Galectin-accessible binding sites in testes. Normal human testes (a, b) and SCOS (c, d). Expression of galectin-1 -specific binding sites (a, c) 
and galectin-3-specific binding sites (b, d). X 120 
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Control reactions included competitive inhibition with 
0.2M lactose and 0.5 mg asialofetuin (ASF)/ml PBS 
buffer and omission of the incubation step with the 
labeled marker to exclude any nonspecific staining by 
binding of the kit reagents. Positive controls were 
performed with galactoside-specific Viscum album 
agglutinin (Gabius et al., 1991). In addition, antisera 
against galectin-l and -3 have been used at a final 
dilution of 1:200 and an avidin-peroxidase kit as 
described above. To intensify immunostaining for 
galectin-specific binding sites, galectins-l and -3 (0.1 to 
1.0 pglml) have been used together with anti-galectins 
(1:200) and processed as described above. Using this 
procedure immunostaining was markedly increased. 
Staining intensity was semiquantitatively scored on a 4- 
grade scale. In the following section (Results) the use of 
the term "galectin-specific binding sites" will only refer 
to those identified by this procedure. 
Results 
Sertoli cells in normal testes displayed a moderate 
cytoplasmic and weak nuclear staining for galectin-l- 
specific binding sites compared to a weak cytoplasmic 
staining in germ cells. Galectin-3-specific binding sites 
were expressed in Sertoli cells less intensely than 
galectin-l-specific epitopes (mean score 2.25 for 
galectin-l and 1.50 for galectin-3). Germ cells disclosed 
a weak expression. Tubular walls were devoid of 
accessible sites for both galectins (Fig. la, b). 
In SCOS, galectin-l-specific binding was moderate 
to strong and more pronounced than galectin-3-binding 
by Sertoli cells (mean score 4.00 and 2.25). Tubular 
walls remained negative for galectin staining under these 
conditions. In Sertoli cells of normal testes galectin-l- 
specific binding sites were predominant, whereas an 
indication for cell-type specificity was underscored by 
the relative abundance of galectin-l and -3 binding in 
SCOS (Fig. la-d). The ratio of galectin-l/galectin-3 
staining intensity (score ratio) was 1.50 for normal testis 
and 1.78 for SCOS showing a relative increase of 
galectin-3 binding in the latter. Inhibition experiments 
with ASF/lactose markedly diminished the galectin 
staining ascertaining the dependence of signal generation 
on carbohydrate-specific binding of the galectins. 
Additionally, a search for endogenous galectin 
Fig. 2. Galectin expression in human testes. Normal human testes (a, b) and SCOS (c, d). Expression of galectin-l (a, c) and galectin-3 (b, d). a, X 
400; b, d, X 120; c X 240 
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immunoreactivity by the use of anti-galectin IgG 
fractions was performed. Galectin expression was 
measured with specific antisera against galectin-l and 
-3. We observed a strong expression of galectin-l in 
Sertoli cell cytoplasm of all samples (score 4.00). There 
was no difference between normal and SCOS specimens. 
The anti-galectin-3 stained Leydig cells only (score 
3.00) in normal testis, but gave no positive signals on 
either Sertoli cells or germ cells. In SCOS, a weak to 
moderate nuclear staining of Sertoli  cel ls  was 
demonstrated (score 2.00; Fig. 2a-d). Galect in- l  
immunoreactivity was found along the tubular wall in 
normal testis (Fig. 2a). In SCOS the tubular walls gave a 
discontinuous staining (Fig. 2c). Galectin-3 immuno- 
reactivity was not found in the tubular walls of testes 
from normal and SCOS samples (Fig. 2b, d). Negative 
controls with omission of the antisera against galectins 
yielded no staining. 
Discussion 
Since the original description of SCOS, numerous 
clincial and morphological studies have been published 
to improve the definition of features of this disease (Del 
Castillo et al., 1947). Though SCOS may occur as an 
idiopathic condition, Turek et al. (1995) found germ cell 
aplasia in 38% of their cases to be associated with an 
underlying disease (chemotherapeutics agents or 
radiotherapy for cancer treatment and others). 
In SCOS contrasting with the normal human testes, 
different types of Sertoli cell differentiation have been 
described and associated with the severity of impairment 
of Sertoli cell function. Terada and Hatakeyama (1991) 
described two types of Sertoli cells in SCOS: one 
resembling the normal adult Sertoli cells and another 
with a vimentin distribution resembling fetal Sertoli 
cells. A transient expression of cytokeratins has been 
observed (Stosiek et al., 1990; Bergmann and Kliesch, 
1994). Nistal et al. (1990) distinguished four types of 
Sertoli cells: (1) normal adult mature cells showing an 
indented nucleus, grossly triangular in  shape with a 
prominent tripartite nucleolus; (2) immature cells with 
round, regularly shaped nuclei and immature cytoplasm; 
(3) dysgenetic cells harboring immature nuclei and a 
nearly mature cytoplasm with less developed organelles 
and (4) involuting cells with very irregularly shaped 
nuclei and a cytoplasm containing abundant lipid 
droplets and residual bodies with atypical inter-Sertoli 
junctions. They observed types (l), (3) and (4) in SCOS. 
The morphological changes of Sertoli cells are not 
specific for SCOS but may occur in other pathological 
conditions as well (Schulze et al., 1976). The expression 
of plant lectin-reactive glycoconjugates by Sertoli cells 
of SCOS has not been found to be different from normal 
testis (Wollina et al., 1989a,b). However, endogenous 
lectins have so far not been introduced to study ligand 
presentative for all these types, as initiated in this study. 
Labeled galectins proved to be suitable glycohisto- 
chemical probes. 
Upon comparing staining extents a relative increase 
of galectin binding by Sertoli cells in SCOS compared to 
normal testis was detectable. The galectin-llgalectin-3 
binding ratio was higher in SCOS (1.78) vs. normal 
testis (1.50) (Fig. la-d). Staining for galectin-l and -3 
revealed differences between normal testis and SCOS. 
Whereas galectin-l-dependent cytoplasmic immuno- 
reactivity was found in Sertoli cells of normal and 
pathological samples, galectin-3 expression was only 
seen in nuclei of Sertoli cells in SCOS (Fig. 2a-d). As 
already emphasized in the introduction, nuclear presence 
of a galectin can be an indication for a role in pre- 
mRNA processing (Patterson et al., 1997). 
A further hallmark of SCOS is the thickening of the 
lamina propria of seminiferous tubules. Both in normal 
testis and in SCOS, laminin and collagen type IV are 
found in the tubulare wall and the peritubular cell layers. 
Sertoli  cel ls  do not only contain laminin but the 
distribution of laminin and collagen IV suggests their 
secretion by Sertoli cells (Pollanen et al., 1985; Skinner 
et al., 1985). Their distribution is disturbed in SCOS 
(Pollanen et al., 1985). 
Wollina et al. (1989b) described a selective loss of 
mannosyl residues in the adluminal part of tubular walls 
in SCOS. In the present investigation, we found neither 
galectin-l or -3 expression nor specific binding sites in 
tubular walls of normal and SCOS testis. Galectin-l 
immunoreactivity was expressed in normal and SCOS 
testis but was rather discontinous in the latter. 
Sertoli cells control germ cell number by secretion 
of the Fas ligand, which is bound to Fas on germ cells. 
The Fas system is a key pathway of germ cell apoptosis 
(Lee et al., 1997). Owing to a connection to the control 
of apoptosis an increased galectin-3 expression and a 
higher level of galectin-binding sites in Sertoli cells of 
SCOS compared to normal human testis deserves 
attention. This  observation may be related to the 
disturbed laminin desposition in the former (Pollanen et 
al., 1985) andlor inhibition of apoptosis (Yang et al., 
1996; Akahani et al., 1997). In culture, Sertoli cell 
apoptosis is mediated by contact inhibition or serum 
deprivation (Pogan et al., 1997). In vitro, basement 
membrane contact (laminin or Matrigel) prevents Sertoli 
cell apoptosis (Dirami et al., 1995). Since galectins may 
function as accessory adhesion molecules, changes of 
abundance of galectin-specific binding sites in SCOS 
may be associated with disturbed Sertoli cell interaction 
including galectin-reactive extracellular matrix 
components like laminin. Further studies with these non- 
integrin laminin-binding proteins are thus warranted. 
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